These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12243247)

  • 1. Toll-like receptor 9, CpG DNA and innate immunity.
    Ashkar AA; Rosenthal KL
    Curr Mol Med; 2002 Sep; 2(6):545-56. PubMed ID: 12243247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG motifs in bacterial DNA and their immune effects.
    Krieg AM
    Annu Rev Immunol; 2002; 20():709-60. PubMed ID: 11861616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9.
    Takeshita F; Gursel I; Ishii KJ; Suzuki K; Gursel M; Klinman DM
    Semin Immunol; 2004 Feb; 16(1):17-22. PubMed ID: 14751759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.
    Tabeta K; Georgel P; Janssen E; Du X; Hoebe K; Crozat K; Mudd S; Shamel L; Sovath S; Goode J; Alexopoulou L; Flavell RA; Beutler B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3516-21. PubMed ID: 14993594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.
    Hemmi H; Kaisho T; Takeda K; Akira S
    J Immunol; 2003 Mar; 170(6):3059-64. PubMed ID: 12626561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG DNA in the prevention and treatment of infections.
    Dalpke A; Zimmermann S; Heeg K
    BioDrugs; 2002; 16(6):419-31. PubMed ID: 12463765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88.
    Schnare M; Holt AC; Takeda K; Akira S; Medzhitov R
    Curr Biol; 2000 Sep; 10(18):1139-42. PubMed ID: 10996797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.
    Suzuki K; Suda T; Naito T; Ide K; Chida K; Nakamura H
    Am J Respir Crit Care Med; 2005 Apr; 171(7):707-13. PubMed ID: 15640365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential signaling by CpG DNA in DCs and B cells: not just TLR9.
    Verthelyi D; Zeuner RA
    Trends Immunol; 2003 Oct; 24(10):519-22. PubMed ID: 14552833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10.
    He B; Qiao X; Cerutti A
    J Immunol; 2004 Oct; 173(7):4479-91. PubMed ID: 15383579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor signaling in anti-cancer immunity.
    Okamoto M; Sato M
    J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
    Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
    Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.